Skip to main content
SpringerLink
Log in

Prise en charge des métastases cérébrales des cancers du poumon

The treatment of brain metastases in lung cancer

  • Mise Au Point / Update
  • Published:
Oncologie

Résumé

Les métastases cérébrales (MC) de cancer du poumon sont fréquentes et de mauvais pronostic. Leur prise en charge est complexe et a pour but, en même temps, d’éviter la dégradation neurologique et de traiter la maladie extracérébrale. Cette revue détaille la prise en charge des MC de carcinomes bronchiques non à petites cellules et à petites cellules, elle fait le point sur les nouveautés concernant les traitements symptomatiques, la chirurgie, la radiothérapie cérébrale, la chimiothérapie, les traitements ciblés.

Abstract

Brain metastases of lung cancer are common and have a poor prognosis. Their managment is complex, and the objective of the treatment is at the same time to avoid the neurologic degradation and to treat the extracranial disease. In this review, we revised the management of BM in nonsmall cell lung cancer and small cell lung cancer, including advancements in supportive therapy, neurosurgery, radiation therapy, chemotherapy, and targeted therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22:2865–72

    Article  PubMed  Google Scholar 

  2. Nayak L, Lee EQ, Wen PY (2012) Epidemiology of brain metastases. Curr Oncol Rep 14:48–54

    Article  PubMed  Google Scholar 

  3. Schuette W (2004) Treatment of brain metastases from lung cancer: chemotherapy. Lung Cancer Amst Neth 45:S253–S7

    Article  Google Scholar 

  4. Seute T, Leffers P, ten Velde GPM, Twijnstra A (2008) Detection of brain metastases from small cell lung cancer: consequences of changing imaging techniques (CT versus MRI). Cancer 112:1827–34

    Article  PubMed  Google Scholar 

  5. Gaspar L, Scott C, Rotman M, et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745–51

    Article  CAS  PubMed  Google Scholar 

  6. Gaspar LE, Scott C, Murray K, Curran W (2000) Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 47:1001–6

    Article  CAS  PubMed  Google Scholar 

  7. Sperduto PW, Berkey B, Gaspar LE, et al (2008) A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70:510–4

    Article  PubMed  Google Scholar 

  8. Weickhardt AJ, Scheier B, Burke JM, et al (2012) Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 7:1807–14

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Sperduto PW, Kased N, Roberge D, et al (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419–25

    Article  PubMed  Google Scholar 

  10. Weller M, Stupp R, Wick W (2012) Epilepsy meets cancer: when, why, and what to do about it? Lancet Oncol 13:e375–e82

    Article  PubMed  Google Scholar 

  11. Ryken TC, McDermott M, Robinson PD, et al (2010) The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96:103–14

    Article  CAS  PubMed  Google Scholar 

  12. Faguer R, Terminassian A, Hureaux J, et al (2012) Prise en charge chirurgicale des métastases cérébrales des cancers bronchopulmonaires. RMRA Rev Mal Respir Actual 4: 550–7

    Google Scholar 

  13. Patchell RA, Tibbs PA, Walsh JW, et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494–500

    Article  CAS  PubMed  Google Scholar 

  14. Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al (1994) The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 29:711–7

    Article  CAS  PubMed  Google Scholar 

  15. Mintz AH, Kestle J, Rathbone MP, et al (1996) A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 78:1470–6

    Article  CAS  PubMed  Google Scholar 

  16. Mazeron JJ, Valéry CA, Boisserie G, Cornu P (2012) History of radiosurgery. Cancer Radiother 16:S2–S4

    Article  PubMed  Google Scholar 

  17. Dhermain F, Reyns N, Colin P, et al (2015) Stereotactic radiotherapy in brain metastases. Cancer Radiother 19:25–9

    Article  CAS  PubMed  Google Scholar 

  18. Le Rhun E, Dhermain F, Noël G, et al (2015) Anocef guidelines for the management of brain metastases. Cancer Radiother 19:66–71

    Article  PubMed  Google Scholar 

  19. Yamamoto M, Kawabe T, Sato Y, et al (2014) Stereotactic radiosurgery for patients with multiple brain metastases: a casematched study comparing treatment results for patients with 2–9 versus 10 or more tumors. J Neurosurg 121:16–25

    PubMed  Google Scholar 

  20. Kocher M, Soffietti R, Abacioglu U, et al (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 29:134–41

    Article  PubMed  Google Scholar 

  21. Tsao MN, Lloyd N, Wong RKS, et al (2012) Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev 4:CD003869

    PubMed  Google Scholar 

  22. Reck M, Popat S, Reinmuth N, et al (2014) Metastatic nonsmall- cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25:iii27–iii39

    Article  PubMed  Google Scholar 

  23. Whole brain radiotherapy for brain metastases from non-small lung cancer: Quality of life (QoL) and overall survival (OS) results from the UK Medical Research Council QUARTZ randomised clinical trial (ISRCTN 3826061). J Clin Oncol [Internet]. [cité 6 mars 2016]. Disponible sur: http://meetinglibrary.asco.org/content/149588-156

  24. Andrews DW, Scott CB, Sperduto PW, et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363:1665–72

    Article  PubMed  Google Scholar 

  25. McDuff SGR, Taich ZJ, Lawson JD, et al (2013) Neurocognitive assessment following whole brain radiation therapy and radiosurgery for patients with cerebral metastases. J Neurol Neurosurg Psychiatry 84:1384–91

    Article  PubMed  Google Scholar 

  26. NCCTG N0574 (Alliance): a phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. J Clin Oncol [Internet]. [cité 23 mars 2016]. Disponible sur: http://meetinglibrary. asco.org/content/146056-156

  27. Sahgal A, Aoyama H, Kocher M, et al (2015) Phase III trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 91:710–7

    Article  PubMed  Google Scholar 

  28. Barlesi F, Spano JP, Cortot AB, et al (2015) Systemic treatment of brain metastases from lung cancer. Cancer Radiother 19:43–7

    Article  CAS  PubMed  Google Scholar 

  29. Robinet G, Thomas P, Breton JL, et al (2001) Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe français de pneumo-cancérologie (GFPC) Protocol 95-1. Ann Oncol 12:59–67

    Article  CAS  PubMed  Google Scholar 

  30. Moro-Sibilot D, Smit E, de Castro Carpeño J, et al (2015) Nonsmall cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: analysis from the European FRAME study. Lung Cancer 90:427–32

    Article  PubMed  Google Scholar 

  31. Barlesi F, Gervais R, Lena H, et al (2011) Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). Ann Oncol 22:2466–70

    Article  CAS  PubMed  Google Scholar 

  32. Bailon O, Chouahnia K, Augier A, et al (2012) Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma. Neuro Oncol 14:491–5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Besse B, Le Moulec S, Mazières J, et al (2015) Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase II Study. Clin Cancer Res 21:1896–903

    Article  CAS  PubMed  Google Scholar 

  34. Heon S, Yeap BY, Lindeman NI, et al (2012) The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res 18:4406–14

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Dempke WCM, Edvardsen K, Lu S, et al (2015) Brain metastases in NSCLC — are TKIs changing the treatment strategy? Anticancer Res 35:5797–806

    CAS  PubMed  Google Scholar 

  36. Schuler M, Wu YL, Hirsh V, et al (2016) First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol 11:380–90

    Article  PubMed  Google Scholar 

  37. nscl.pdf [Internet]. [cité 6 mars 2016]. Disponible sur: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

  38. Perrot E, Peloni JM, Biau J, et al (2016) Référentiel sur les métastases cérébrales: actualisation 2016. ARISTOT. Téléchargeable sur http://espacecancer.sante-ra.fr/Pages/referentiels.aspx et sur www.lecancer.fr

    Google Scholar 

  39. Remon J, Planchard D (2015) AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients. Future Oncol 11:3069–81

    Article  CAS  PubMed  Google Scholar 

  40. Costa DB, Shaw AT, Ou SHI, et al (2015) Clinical experience with crizotinib in patients with advanced ALK-rearranged nonsmall- cell lung cancer and brain metastases. J Clin Oncol 33:1881–8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Gadgeel SM, Gandhi L, Riely GJ, et al (2014) Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 15:1119–28

    Article  CAS  PubMed  Google Scholar 

  42. ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). J Clin Oncol [Internet]. [cité 3 mars 2016]. Disponible sur: http://meetinglibrary.asco.org/content/144861-156

  43. Johung KL, Yeh N, Desai NB, et al (2016) Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol 34:123–9

    Article  CAS  PubMed  Google Scholar 

  44. Dziadziuszko K, Szurowska E, Pienkowska J, et al (2014) Miliary brain metastases in a patient with ROS1-rearranged lung adenocarcinoma: a case report. J Thorac Oncol 9:e34–e6

    Article  PubMed  Google Scholar 

  45. Robinson SD, O’Shaughnessy JA, Cowey CL, Konduri K (2014) BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. Lung Cancer 85:326–30

    Article  PubMed  Google Scholar 

  46. Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases. J Clin Oncol [Internet]. [cité 6 mars 2016]. Disponible sur: http://meetinglibrary. asco.org/content/145416-156

  47. Hendriks LEL, Schoenmaekers J, Zindler JD, et al (2015) Safety of cranial radiotherapy concurrent with tyrosine kinase inhibitors in non-small cell lung cancer patients: a systematic review. Cancer Treat Rev 41:634–45

    Article  CAS  PubMed  Google Scholar 

  48. Sperduto PW, Wang M, Robins HI, et al (2013) A phase III trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys 85:1312–8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Aupérin A, Arriagada R, Pignon JP, et al (1999) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341:476–84

    Article  PubMed  Google Scholar 

  50. Slotman B, Faivre-Finn C, Kramer G, et al (2007) Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357:664–72

    Article  CAS  PubMed  Google Scholar 

  51. Seto T (2014) Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): results of a Japanese randomized phase III trial. J Clin Oncol [Internet]. [cité 29 mai 2016]; Disponible sur: http://meetinglibrary.asco.org/content/129034-144

    Google Scholar 

  52. Reveiz L, Rueda JR, Cardona AF (2012) Chemotherapy for brain metastases from small cell lung cancer. Cochrane Database Syst Rev 6:CD007464

    PubMed  Google Scholar 

  53. Korfel A, Oehm C, von Pawel J, et al (2002) Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. a multicentre phase II study. Eur J Cancer 38:1724–9

    Article  CAS  PubMed  Google Scholar 

  54. Pietanza MC, Kadota K, Huberman K, et al (2012) Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res 18:1138–45

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de pneumologie et pathologie professionnelle, CHI de Créteil, 40, avenue de Verdun, F-94010, Créteil cedex, France

    I. Monnet, G. Rousseau-Bussac, L. Jabot & C. Chouaid

Authors
  1. I. Monnet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Rousseau-Bussac
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Jabot
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Chouaid
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. Monnet.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Monnet, I., Rousseau-Bussac, G., Jabot, L. et al. Prise en charge des métastases cérébrales des cancers du poumon. Oncologie 18, 376–384 (2016). https://doi.org/10.1007/s10269-016-2636-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-016-2636-2

Mots clés

Keywords

Search

Navigation